NASDAQ · Biotechnology

CNSP (CNSP) Stock

$5.40 +0.75% NASDAQ: CNSP Healthcare

Valuation

MetricValue
Price$5.40
Market Cap$3.10M
P/E Ratio-0.14
P/B Ratio0.59
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$12.36
52-Week Low$1.90
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-320.00%
ROA-177.78%
ROCE-320.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity3.29
Current Ratio2.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-14.0M$-15.0M$-19.0M$-15.0M$-16.0M
Net Profit$-14.0M$-15.0M$-19.0M$-15.0M$-16.0M
EPS$-495027.00$-336499.00$-150114.00$-466.44$-35.75
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$9.0M$13.0M$2.0M$9.0M$9.0M
Total Liabilities$2.0M$5.0M$6.0M$3.0M$4.0M
Cash$5.0M$10.0M$1.0M$6.0M$7.0M
Borrowings$0$0$0$0$0

Latest News

CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment ACCESS Newswire · Jun 8, 2026 CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress ACCESS Newswire · May 20, 2026 CNS Pharmaceuticals Registers 9.79 Million Shares for Selling Holders MT Newswires · May 19, 2026 Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6 24/7 Wall St. · May 14, 2026 CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress ACCESS Newswire · May 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-14.0M$-11.0M$-14.0M$-17.0M$-14.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$3.0M$0$1.0M
Net Cash Flow$-9.0M$5.0M$-10.0M$6.0M$1.0M
Free Cash Flow$-14.0M$-11.0M$-14.0M$-17.0M$-14.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-489.44%
Quick Ratio0.88
Interest Coverage—
Return 1Y-54.97%
Return 3Y-99.99%
Return 5Y-100.00%

Ownership

Insiders Held0.49%
Institutions Held12.51%
Institutions Float Held12.57%
Institutional HolderSharesReport Date
Stonepine Capital Management, LLC61,0002026-03-31
Ikarian Capital, LLC45,8302026-03-31
Geode Capital Management, LLC23,1892026-03-31
Boothbay Fund Management, LLC13,5242026-03-31
Tower Research Capital LLC (TRC)1,3102026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CMND $1.62 +0.52% -0.79 $2.41M 0.00%
ENSCEnsysce Biosciences, Inc. $0.26 -1.95% -0.08 $2.38M 0.00%
GRI $1.46 -5.81% -0.33 $131155 0.00%
KTTA $0.45 -2.17% -0.25 $3.35M 0.00%
NLSPNLS Pharmaceutics AG $2.91 -12.61% -0.43 $919601 0.00%

About CNSP

CNSP is led by CEO Rami Levin, employs 4 people, headquartered in US, publicly traded since 2019.

CNSP stock trades at $5.40 with a market capitalization of $3.10M. The stock is valued at a price-to-earnings (P/E) ratio of -0.14, price-to-book of 0.59, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.90 and $12.36, and currently trades 56.3% below its 52-week high.

On profitability, CNSP generates a return on equity (ROE) of -320.00%, return on capital employed of -320.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides